HIM
PLX icon

Hillsdale Investment Management’s Protalix BioTherapeutics PLX Stock Holding History

Hillsdale Investment Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-118,100
Closed -$175K – 716
2025
Q2 		$175K Buy
118,100
+2,000
+2% +$4.09K 0.01% 466
2025
Q1 		$297K Buy
+116,100
New +$277K 0.02% 393

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Hillsdale Investment Management's PLX Position: Q3 2025 in Review

Hillsdale Investment Management sold out of Protalix BioTherapeutics (PLX) in Q3 2025, closing a stake of 118,100 shares — an estimated $175K sold.

Hillsdale Investment Management first reported a position in PLX in Q1 2025 and held it in 2 quarters. The position peaked at $297K in Q1 2025. 77 funds tracked by Wall St. Rank hold PLX as of Q3 2025.

  • Hillsdale Investment Management reported no remaining Protalix BioTherapeutics position as of Q3 2025 after selling out during the quarter.
  • Hillsdale Investment Management sold 118,100 Protalix BioTherapeutics shares in Q3 2025, an estimated $175K.
  • Hillsdale Investment Management first reported a position in Protalix BioTherapeutics in Q1 2025 and held it in 2 quarters.
  • Hillsdale Investment Management's Protalix BioTherapeutics position peaked at $297K in Q1 2025.
  • 77 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2025.

Based on Hillsdale Investment Management's 13F filing for Q3 2025, filed 10 Nov 2025.